Edwards Lifesciences Corporation Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Edwards Lifesciences Corporation (EW) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of $248.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-04
- Edwards Lifesciences Corporation comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $248.10M, a 22.93% decline year-over-year.
- Edwards Lifesciences Corporation comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $397.70M, a 14.81% increase year-over-year.
- Edwards Lifesciences Corporation comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $103.30M, a 73.67% decline year-over-year.
- Edwards Lifesciences Corporation comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $304.00M, a 89.99% decline year-over-year.
- Edwards Lifesciences Corporation comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was $1.08B, a 74.19% decline from fiscal 2024.
- Edwards Lifesciences Corporation comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $4.17B, a 195.29% increase from fiscal 2023.
- Edwards Lifesciences Corporation comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was $1.41B, a 0.93% decline from fiscal 2022.
- Edwards Lifesciences Corporation comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $1.42B, a 5.43% decline from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $248.10M 10-Q · filed 2026-08-04 | $645.80M 10-Q · filed 2026-08-04 | $749.10M derived: sum of 3 quarters · filed 2026-08-04 | $1.05B derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $397.70M 10-Q · filed 2026-05-06 | $501.00M derived: sum of 2 quarters · filed 2026-05-06 | $805.00M derived: sum of 3 quarters · filed 2026-05-06 | $1.13B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $103.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $407.30M derived: sum of 2 quarters · filed 2026-02-25 | $729.20M derived: sum of 3 quarters · filed 2026-08-04 | $1.08B 10-K · filed 2026-02-25 |
| 2025-09-30 | $304.00M 10-Q · filed 2025-11-05 | $625.90M derived: sum of 2 quarters · filed 2026-08-04 | $972.30M 10-Q · filed 2025-11-05 | $1.36B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $321.90M 10-Q · filed 2026-08-04 | $668.30M 10-Q · filed 2026-08-04 | $1.06B derived: sum of 3 quarters · filed 2026-08-04 | $4.10B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $346.40M 10-Q · filed 2026-05-06 | $738.70M derived: sum of 2 quarters · filed 2026-05-06 | $3.78B derived: sum of 3 quarters · filed 2026-05-06 | $4.15B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $392.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.43B derived: sum of 2 quarters · filed 2026-02-25 | $3.81B derived: sum of 3 quarters · filed 2026-02-25 | $4.17B 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.04B 10-Q · filed 2025-11-05 | $3.42B derived: sum of 2 quarters · filed 2025-11-05 | $3.78B 10-Q · filed 2025-11-05 | $4.15B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $378.10M 10-Q · filed 2025-08-06 | $738.60M 10-Q · filed 2025-08-06 | $1.12B derived: sum of 3 quarters · filed 2026-02-25 | $1.50B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $360.50M 10-Q · filed 2025-05-06 | $737.50M derived: sum of 2 quarters · filed 2026-02-25 | $1.13B derived: sum of 3 quarters · filed 2026-02-25 | $1.43B derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $377.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $766.10M derived: sum of 2 quarters · filed 2026-02-25 | $1.07B derived: sum of 3 quarters · filed 2026-02-25 | $1.41B 10-K · filed 2026-02-25 |
| 2023-09-30 | $389.10M 10-Q · filed 2024-11-06 | $694.50M derived: sum of 2 quarters · filed 2024-11-06 | $1.03B 10-Q · filed 2024-11-06 | $1.43B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $305.40M 10-Q · filed 2024-07-31 | $645.40M 10-Q · filed 2024-07-31 | $1.04B derived: sum of 3 quarters · filed 2025-02-28 | $1.36B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $340.00M 10-Q · filed 2024-04-29 | $739.50M derived: sum of 2 quarters · filed 2025-02-28 | $1.05B derived: sum of 3 quarters · filed 2025-02-28 | $1.42B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $399.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $711.40M derived: sum of 2 quarters · filed 2025-02-28 | $1.08B derived: sum of 3 quarters · filed 2025-02-28 | $1.42B 10-K · filed 2025-02-28 |
| 2022-09-30 | $311.90M 10-Q · filed 2023-10-27 | $680.50M derived: sum of 2 quarters · filed 2023-10-27 | $1.03B 10-Q · filed 2023-10-27 | |
| 2022-06-30 | $368.60M 10-Q · filed 2023-07-28 | $713.30M 10-Q · filed 2023-07-28 | ||
| 2021-12-31 | $1.51B 10-K · filed 2024-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |